MDMA for the Treatment of Negative Symptoms in Schizophrenia
Journal of Clinical Medicine June 7, 2022 Mitchell Arnovitz, Andrew Spitzberg, Ashkhan J. Davani et al. 29 citations
The profound economic burden of schizophrenia is due, in part, to the negative symptoms of the disease, which can severely limit daily functioning. There is much debate in the field regarding their measurement and classification and there are no FDA-approved treatments for negative symptoms despite an abundance of research. 3,4-Methylenedioxy methamphetamine (MDMA) is a schedule I substance...